Open AccessReal-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
Author(s) -
Raffaele Campisi,
Claudia Crimi,
Santi Nolasco,
Bianca Beghé,
Leonardo Antonicelli,
Gabriella Guarnieri,
Nicola Scichilone,
Morena Porto,
Luigi Macchia,
Giulia Scioscia,
Maria Pia Foschino Barbaro,
Alberto Papi,
Nunzio Crimi
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s312123
Subject(s) - medicine , dupilumab , asthma , bronchodilator , exhaled nitric oxide , bronchoconstriction
Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for severe asthma (SA). A Named Patients Program (NPP) was created in Italy before its commercial availability for SA patients with no other available therapeutic options. We aimed to assess the real-world effectiveness of dupilumab in patients with SA and unmet needs.